The Imidazacridine Derivative LPSF/AC-05 Induces Apoptosis, Cell Cycle Arrest, and Topoisomerase II Inhibition in Breast Cancer, Leukemia, and Lymphoma

细胞凋亡 癌症研究 拓扑异构酶 白血病 乳腺癌 淋巴瘤 医学 癌症 内科学 化学 DNA 生物化学
作者
Mardonny Bruno de Oliveira Chagas,Valécia de Cássia Mendonça da Costa,Claudio Montenegro,Maria do Carmo Alves de Lima,Michelle Melgarejo da Rosa,Michelly Cristiny Pereira,Moacyr Jesus Barreto de Melo Rêgo,Maíra Galdino da Rocha Pitta
出处
期刊:Current Cancer Drug Targets [Bentham Science Publishers]
卷期号:25 (5): 431-444 被引量:1
标识
DOI:10.2174/0115680096290753240613114122
摘要

Introduction: Cancer is one of the major causes of morbidity and mortality worldwide. Current treatments for both solid and hematological tumors are associated with severe adverse effects and drug resistance, necessitating the development of novel selective antineoplastic drugs Methods: The present study describes the antitumor activity of the imidazacridine derivative 5-acridin-9-ylmethylidene-2-thioxoimidazolidin-4-one (LPSF/AC05) in breast cancer, leukemia, and lymphoma cells. Cytotoxicity assays were performed in PBMC and in breast cancer, leukemia, and lymphoma cell lines using the MTT method. Changes in cell cycle progression and apoptosis were assessed using flow cytometry. Moreover, topoisomerase II inhibition assays were performed. LPSF/AC05 exhibited cytotoxicity in six of the nine cell lines tested. Results: The best results for leukemia and lymphoma were observed in the Toledo, Jurkat, and Raji cell lines (IC50 = 27.18, 31.04, and 33.36 M, respectively). For breast cancer, the best results were observed in the triple-negative cell line MDA-MB-231 (IC50 = 27.54 μM). The compound showed good selectivity, with no toxicity to normal human cells (IC50 > 100M; selectivity index > 3). Cell death was primarily induced by apoptosis in all cell lines. Furthermore, LPSF/AC05 treatment induced cell cycle arrest at the G0/G1 phase in leukemia/lymphoma and at the G2/M phase in breast cancer. Finally, topoisomerase II was inhibited. Conclusion: These results indicate the potential application of LPSF/AC05 in cancer therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
XYJ89757完成签到,获得积分10
1秒前
秋风的应助被zhiren采纳,获得10
1秒前
郑睿涛发布了新的文献求助10
2秒前
3秒前
4秒前
晚云烟月完成签到,获得积分10
4秒前
5秒前
会发光的小叶子的应助被王达采纳,获得20
5秒前
6秒前
充电宝的应助被和蔼的茅草根采纳,获得10
6秒前
LEETHEO发布了新的文献求助10
6秒前
快乐小狗完成签到,获得积分10
7秒前
天天快乐的应助被小蝴蝶采纳,获得10
7秒前
8秒前
嘻嘻哈哈的应助被静夜枫眠采纳,获得10
8秒前
甜蜜妙竹完成签到,获得积分10
8秒前
9秒前
聪慧的晓蓝完成签到,获得积分20
9秒前
xzy666的应助被xbjcdlnxd采纳,获得10
9秒前
10秒前
山夏川上山完成签到 ,获得积分10
11秒前
13秒前
14秒前
在水一方的应助被坚强的茗茗采纳,获得10
15秒前
爱看文献的神树完成签到 ,获得积分10
16秒前
风吹麦浪发布了新的文献求助10
16秒前
小蝴蝶完成签到,获得积分10
16秒前
你一定能发表完成签到,获得积分10
17秒前
牧百川发布了新的文献求助10
17秒前
英姑的应助被lzh采纳,获得10
17秒前
18秒前
思源的应助被tlc_191026采纳,获得30
18秒前
KYT完成签到,获得积分10
18秒前
KATHY完成签到 ,获得积分10
19秒前
20秒前
郑睿涛发布了新的文献求助10
21秒前
陈乐宁2024完成签到,获得积分10
21秒前
kyou完成签到,获得积分10
22秒前
希望天下0贩的0的应助被ccc采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183423
求助须知:如何正确求助?哪些是违规求助? 9572834
关于积分的说明 21827410
捐赠科研通 7780522
什么是DOI,文献DOI怎么找? 3434016
关于科研通互助平台的介绍 2558189
邀请新用户注册赠送积分活动 2480357